Fig. 5: SBI-756 treatment reduces protein synthesis following 16 h of treatment. | British Journal of Cancer

Fig. 5: SBI-756 treatment reduces protein synthesis following 16 h of treatment.

From: Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax

Fig. 5

We treated cells with vehicle or inhibitors (MLN0128 (30 nM), rapamycin (10 nM), SBI-756 250 nM) and measured puromycin incorporation after 16 hr. a parental OCI-LY1 cells; b OCI-LY1 that were induced to resistance against SBI-756 (1 µM); c OCI-LY7; d OCI-LY8; e SU-DHL-6 cells. *p < 0.05, **p < 0.01. One-sample t-test vs. DMSO control. n = 3. f OCI-LY1 cells were treated with venetoclax 10 nM, MLN0128 100 nM, SBI-756 250 nM as single agents or in combination, as indicated. We have assessed their viability after 4, 16, 24 or 48 h of treatment using annexing V and PI staining and flow cytometry analysis. *p < 0.05, **p < 0.01. One-way ANOVA, compared to venetoclax as single agent.

Back to article page